Arbutus Biopharma Corporation (NASDAQ:ABUS) saw an upside of 6.60% to close Monday at $4.20 after adding $0.26 on the day. The 5-day average trading volume is 4,078,460 shares of the company’s common stock. It has gained $4.41 in the past week. An average of 2,945,550 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,662,608.
ABUS’s 1-month performance is -4.11% or -$0.18 on its low of $3.73 reached on 10/07/21. The company’s shares have touched a 52-week low of $2.43 and high of $5.87, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, ABUS has achieved 18.31% or $0.65. However, the current price is down -28.45%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Feb 09, 245 days have gone by since the last insider trading activity for Arbutus Biopharma Corporation (ABUS). McElhaugh Michael J. (Chief Business Officer) most recently sold 20,000 shares at $5.00 per share on Feb 09. This transaction cost the insider $100,000. Chief Business Officer, McElhaugh Michael J., sold 40,000 shares at a price of $5.00 on Dec 14.
Arbutus Biopharma Corporation (ABUS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.ABUS stock has a beta of 2.66. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 51.60.
Arbutus Biopharma Corporation’s quick ratio for the period ended June 29 was 9.40, with the current ratio over the same period at 9.40 meaning that ABUS stock is able to fulfill its debt obligations. The trailing 12-month EBITDA margin is -799.70%. The firm’s gross profit as reported stood at $64.25 million against revenue of $6.91 million.
For the quarterly period ending June 29 this year, Arbutus Biopharma Corporation’s cash and short-term investments amounted to $47.43 million against total debt of $2.83 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ABUS to announce -$0.22 per share in earnings in its latest quarter, but it posted -$0.23, representing a -4.50% surprise. EBITDA for the quarter stood at more than -$18.21 million. ABUS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 34.55 million, with total debt at $2.83 million. Shareholders hold equity totaling $99.16 million
Let’s look briefly at Arbutus Biopharma Corporation (ABUS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 52.46% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.82%.
The stock’s 5-day moving average is $4.09, reflecting a +1.69% or $0.07 change from its current price. ABUS is currently trading -1.18% above its 20-day SMA, +57.30% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +56.13% and +3.70% respectively.
Stochastic %K and %D was 34.65% and 26.54% and the average true range (ATR) pointed at 0.29. The RSI (14) points at 55.01%, while the 14-day stochastic is at 46.53% with the period’s ATR at 0.27. The stock’s 9-day MACD Oscillator is pointing at -0.08 and -0.20 on the 14-day charts.
In the most recent analyst report for Arbutus Biopharma Corporation (NASDAQ: ABUS), Jefferies launched coverage with a Hold rating.